Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inhaled liposomal tobramycin - Axentis Pharma AG

Drug Profile

Inhaled liposomal tobramycin - Axentis Pharma AG

Alternative Names: ARB-CF0223; Fluidosome tobramycin; Fluidosomes-tobramycin

Latest Information Update: 23 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator aRigen
  • Developer Axentis Pharma
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 07 Aug 2015 Phase-II development is ongoing in Europe
  • 16 Jul 2009 Tobramycin liposomal receives orphan drug status for Cystic fibrosis-associated respiratory tract infections caused by Burkholderia cepacia in USA
  • 04 Sep 2008 Phase-IIa clinical trials in Cystic fibrosis-associated respiratory tract infections in Europe (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top